CSPHF.US CStone Pharmaceuticals

Healthcare Biotechnology USA Stocks
0.6890 USD
Close of Nov 14, 2026
0.5950 1.01
Market cap
USD 1.10B
P/E
-
P/B
5.67x
ROE
-77.0%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 1 quarter up to Jun 2026.

Is CSPHF.US undervalued?

Graham number

The Graham number of CStone Pharmaceuticals cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

CStone Pharmaceuticals fundamental analysis

No fundamental analysis for CStone Pharmaceuticals yet.

CStone Pharmaceuticals stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About CStone Pharmaceuticals

CStone Pharmaceuticals, a biopharmaceutical company, researches and develops anti-cancer therapies to address the unmet medical needs of cancer patients in Mainland China and internationally. The company offers CEJEMLY (sugemalimab), a monoclonal antibody against programmed death (PD) ligand 1 for the treatment of non-small cell lung cancer (NSCLC), gastric adenocarcinoma/gastroesophageal junction adenocarcinoma, esophageal squamous cell carcinoma, and relapsed or refractory…

Full company profile